In Depth 13 Dec 2024
Is China the future of biotech?
Delve into the ongoing transformation of China’s biotech industry in the last 10 years and in the future evolving geopolitical context.
In Depth
- Latest Posts
In Depth 11 Dec 2024
Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
In Depth 9 Dec 2024
CAR-T cell therapy for lupus: An emerging field with great potential
Discover how the emerging field of using CAR-T cell therapy to treat lupus could offer a potential cure for the autoimmune disorder.
In Depth 5 Dec 2024
The biggest private biotech investments in November 2024
The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024.
In Depth 4 Dec 2024
Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments
There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner.
In Depth 2 Dec 2024
The rise of cancer vaccines: A new era in immunotherapy
Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors.
ADVERTISEMENT
ADVERTISEMENT
In Depth 27 Nov 2024
Charcot–Marie–Tooth disease: what’s going on in the clinical field?
In this article, we take a look at the various treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.
In Depth 22 Nov 2024
Can AlphaFold3’s open-source platform revolutionize the way we discover drugs?
Find out how Google DeepMind’s AlphaFold3 platform could help scientists revolutionize the field of drug discovery.
In Depth 21 Nov 2024
Huntington’s disease: a therapeutic field on a bumpy ride
For years, biotechs have been trying to develop medicines to cure the disease but much to no avail. Now, as clinical studies advance, there is hope.
In Depth 20 Nov 2024
Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024
The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials.
In Depth 18 Nov 2024
What is Abcam’s founder, Jonathan Milner, up to?
Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.
In Depth 13 Nov 2024
Sleep apnea: biotechs snore points in the therapeutic space
Therapeutic strides in biotech are proving to help address different stages of the sleep apnea.
ADVERTISEMENT
